. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Surg Pathol Clin. 2019 Sep 27;12(4):921–930. doi: 10.1016/j.path.2019.08.002

Table 2.

Molecular therapeutic targets in advanced thyroid carcinoma: selective tyrosine kinase inhibitors and their effects in thyroid carcinoma.

Drugs	Targets	Cancers treated
Sorafenib ⁵³	VEGFR, PDGFR, RET/PTC, BRAF, C-KIT	RAI-refractory DTC, ATC MTC
Lenvatinib ⁵³	VEGFR, PDGFR, FGFR, RET/PTC, C-KIT	RAI-refractory DTC ATC MTC
Cabozantinib ⁵⁴	VEGFR, RET, MET	MTC
Vandetanib ⁵⁵	VEGFR, EGFR, RET	MTC
Vemurafenib ⁵⁶	BRAF	RAI-refractory BRAF^V600E-mutated PTC
Debrafenib ⁵⁸	BRAF	RAI-refractory BRAF^V600E-mutated PTC
Selumetinib ⁵⁹	MEK1, MEK2	RAI-refractory DTC

DTC: differentiated thyroid carcinoma, RAI: radioactive iodine.